Anti-Müllerian hormone: Correlation with testosterone and oligo- Or amenorrhoea in female adolescence in a population-based cohort study

Human Reproduction (Impact Factor: 4.57). 07/2014; 29(10). DOI: 10.1093/humrep/deu182
Source: PubMed


STUDY QUESTIONS Can serum anti-Müllerian hormone (AMH) levels measured in female adolescents predict polycystic ovary syndrome (PCOS)-associated
features in adolescence and early adulthood?

Download full-text


Available from: Hany Lashen, Jul 30, 2014
  • Source
    • "pooled the results of all study subjects for the correlation of AMH with metabolic indices, which may have diluted any observed effect inherently related to the pathophysiology of PCOS. In all mentioned studies, AMH was shown to be elevated in women with PCOS compared to healthy controls [31] [32] [37] [38], in correspondence with other literature [21]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The final hallmark of diminishing ovarian reserve is menopause, a state known to be inextricably linked to the deterioration of female cardiovascular health. The menopausal transition is associated with an increased risk of future cardiovascular morbidity and mortality, irrespective of chronological age. The aim of this narrative review is to identify studies investigating the association between Anti-Müllerian Hormone (AMH), a marker of ovarian reserve status, and factors of cardio-metabolic risk. Both for regularly cycling women and women with polycystic ovary syndrome (PCOS), current reports are conflicting and heterogeneous, with some indicating presence and others absence of a correlation between AMH and cardio-metabolic risk factors. The occurrence of hypertensive complications in pregnancy, known to increase the risk of later cardiovascular sequelae, is associated with reduced AMH levels in various study populations. Further research remains a prerequisite in order to further elucidate a possible common mechanism for ovarian and cardiovascular decline. More knowledge of the temporal or causal association between ovarian and cardiovascular decline may enable timely identification of women with increased risk of cardiovascular disease or early onset ovarian aging. Following this, AMH may in the future play a role beyond the scope of female reproduction. Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
    Maturitas 01/2015; 80(3). DOI:10.1016/j.maturitas.2014.12.010 · 2.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Laboratory models support an inverse association between anti-Müllerian hormone (AMH) and breast tumor development. Human studies are lacking; one study (N=105 cases, 204 controls) with prospectively-collected serum reported the opposite-an approximate 10-fold increase in breast cancer risk comparing 4th to 1st quartile AMH levels. We investigated the relation between serum AMH levels and breast cancer risk in a case-control (N=452 cases, 902 controls) study nested within the prospective Sister Study cohort of 50,884 women. At enrollment, participants were ages 35-54, premenopausal, and completed questionnaires on medical and family history, lifestyle factors, and demographics. AMH (ng/ml) was measured by ultrasensitive ELISA in serum collected at enrollment and log-transformed for analysis. Multivariate conditional logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CI) to account for matching on age and enrollment year. Mean age at enrollment was 46.8 years with an average 2.9 years from blood draw to breast cancer diagnosis (SD=1.9). AMH concentrations were below the limit of detection (0.003 ng/ml) for ~25% of samples. Compared with samples below the LOD, women with AMH >2.84 ng/ml (90th percentile among controls) had a two-fold increase in breast cancer odds (OR=2.25; 95% CI: 1.26-4.02). For each 1-unit increase in lnAMH, overall breast cancer odds increased by 8% (OR=1.08; 95% CI: 1.02-1.15) and odds of ER-positive, invasive disease increased by 15% (OR=1.15; 95% CI: 1.05-1.25). Our findings demonstrate an overall positive relation between AMH and breast cancer. Copyright © 2015, American Association for Cancer Research.
    Cancer Prevention Research 04/2015; 8(6). DOI:10.1158/1940-6207.CAPR-14-0377 · 4.44 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Wide regional differences in the age-related Anti Mullerian hormone (AMH) regression patterns or age at onset of natural menopause have been reported, possibly reflecting genetic, socioeconomic, environmental, racial or ethnic peculiarities. Moreover, adaptation of AMH levels from different assays using regression functions may lack accuracy and externally defined references for AMH levels may not fully comply with a specific geographical area. The current study aimed to establish an accurate mathematical relationship between AMH serum values and age in a large group of women from Romania, as any consistent difference from previously reported regression models may aid in building specific profiles for the AMH decline with age in this geographical region. Our study pointed out to the quadratic regression as the most fitted pattern of correlation for all the age groups between 24 and 45. To our knowledge the current manuscript is based on the singular study carried out in this geographical region, generating a particular age-related pattern of association between age and serum AMH levels in women, regardless of their subjacent pathologies.
    PLoS ONE 04/2015; 10(4):e0125216. DOI:10.1371/journal.pone.0125216 · 3.23 Impact Factor
Show more